Thought Mylan might snag a generic Advair approval on its second try? Think again. On Wednesday, the company said an FDA rejection for its copy of the GlaxoSmithKline respiratory behemoth was on the way, thanks to “minor deficiencies” in its
read moreRebel investors earlier this month called for changes at Allergan, and now the company has appointed a new director. More: Allergan brings in Abbott veteran for board position after investors demand change Source: fierce
read moreAnother day, another approval for Merck immuno-oncology star Keytruda. On Wednesday, the drug picked up an FDA green light to treat patients with a rare type of non-Hodgkin lymphoma whose cancer has come back after two or more prior lines
read moreGlaxoSmithKline’s ViiV Healthcare already has Juluca, the first complete two-drug HIV therapy, for patients who are virally suppressed. Now, it has new data to back its dual-drug expansion into treatment-naïve patients, but analysts want to see more data before giving
read moreA lawsuit from Massachusetts is the first to target Purdue executives and directors, according to the state’s attorney general. More: Massachusetts lawsuit names Purdue CEOs, Sackler family for alleged role in opioid epidemic Source: fierce
read moreSome patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG). More: Wales backs NHS use of Actelion’s Uptravi for
read more© 1994 - 2026 B.M. Pharmaceuticals